Prospective multicenter comparison of proliferation and other prognostic factors in lymph node negative lobular invasive breast cancer

Einar Gudlaugsson, Ivar Skaland, Emiel A M Janssen, Paul J. Van Diest, Feja J. Voorhorst, Kjell Kjellevold, Axel Zur Hausen, Jan P A Baak

Research output: Contribution to journalArticlepeer-review

Abstract

Evaluation of prognostic factors in lymph node negative (LNneg) invasive lobular cancers (ILCs). Prospective analysis of proliferation and other prognosticators in 121 LNneg ILCs (119 months median follow-up, range 19-181), without adjuvant chemotherapy. ILC subtype was assessed in accordance with WHO-2003 criteria. Immunohistochemical E-cadherin and estrogen receptor were used. With a median follow up time of 83 months (range 19-181), 30 of the 121 (25%) ILC patients developed distant metastases and 27 (22%) died. None of the cases classified as solid/pleomorphic lobular were E-cadherin or estrogen receptor positive, contrasting the other ILCs. The solid/alveolar ILCs (n = 17) had a worse survival (50%) than the other ILCs (n = 104; 83%, P <0.0001). Mitotic activity index (MAI) (but not nuclear grade or tubule formation) was prognostic with a threshold 0-5 versus >5 (=MAI-5) (contrasting MAI <10 vs. ≥10 in breast cancers in general; 85 and 54% survival, P <0.0001). In multivariate analysis only subtype and MAI but none of the other characteristics had independent prognostic value. Histologic subtype and MAI have independent prognostic value in node negative invasive lobular cancers.

Original languageEnglish (US)
Pages (from-to)35-40
Number of pages6
JournalBreast Cancer Research and Treatment
Volume121
Issue number1
DOIs
StatePublished - May 2010
Externally publishedYes

Keywords

  • Lobular invasive breast cancer
  • Mitotic activity index
  • Prognosis
  • Proliferation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Prospective multicenter comparison of proliferation and other prognostic factors in lymph node negative lobular invasive breast cancer'. Together they form a unique fingerprint.

Cite this